文献速递神经肿瘤

CBX3促进胶质瘤U87细胞增殖并预示不良预后

CBX3 promotes glioma U87 cell proliferation and predicts an unfavorable prognosis.
PubMed 文献 · J Neurooncol · 2019-09-09

该研究通过数据库分析与实验验证,发现CBX3在胶质瘤组织中高表达,且高表达与不良预后相关。敲低CBX3可抑制U87细胞增殖并诱导凋亡,其机制与上调CDKN1A有关,提示CBX3可能成为胶质瘤治疗新靶点。

要点

  • CBX3在胶质瘤中高表达,与肿瘤大小、KPS评分、WHO分级、复发及生存状态相关。
  • 高CBX3表达预示胶质瘤患者无复发生存期和总生存期较差。
  • 敲低CBX3通过上调CDKN1A抑制U87细胞增殖并诱导凋亡。

核心结论

  • 高CBX3表达预测胶质瘤患者不良预后。
  • CBX3通过靶向CDKN1A促进胶质瘤U87细胞生长,可能成为临床治疗新靶点。

研究设计与样本

  • 利用TCGA和Oncomine数据库分析CBX3表达及其与胶质瘤的相关性。
  • 通过qRT-PCR和Western blot检测胶质瘤组织与正常脑组织中CBX3 mRNA和蛋白表达。
  • 回顾性队列研究评估CBX3的预后作用,并分析其与临床病理特征的相关性。
  • 在U87细胞中转染CBX3-shRNA和CDKN1A siRNA,进行体外增殖、细胞周期和凋亡实验。
  • 采用异种移植瘤模型体内评估CBX3的致癌效应和预后价值。

主要发现

  • CBX3在人胶质瘤组织中高表达,且高表达与不良无复发生存期和总生存期相关。
  • 高CBX3表达与肿瘤大小、KPS评分、WHO分级、复发和生存状态相关。
  • 敲低CBX3可显著抑制U87细胞增殖和集落形成能力,通过阻滞细胞于G0/G1期并诱导凋亡实现。
  • 转染shRNA-CBX3后,CDKN1A的mRNA和蛋白表达水平显著上调。
  • 体内实验显示抑制CBX3可限制肿瘤生长和Ki-67表达,同时上调CDKN1A表达;下调CDKN1A可部分恢复U87细胞增殖能力。

临床怎么用

  • CBX3高表达可作为胶质瘤预后不良的潜在生物标志物。
  • 靶向CBX3或其下游CDKN1A通路可能为胶质瘤治疗提供新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chromobox protein homolog 3 (CBX3) is one of the heterochromatin protein 1 (HP1) family members. Among multiple cancers, it is usually overexpressed. However, the mechanism and function of CBX3 in glioma remain incompletely illustrated. METHODS: The expression level of CBX3 as well as its correlation with glioma are detected through TCGA and Oncomine database. The expressions of CBX3 mRNA and protein in glioma tissues and normal brain tissues have been identified by qRT-PCR and Western blot. The prognostic role of CBX3 has been assessed in a retrospective cohort study. Additionally, the correlation between CBX3 expression and the clinicopathological characteristics of glioma patients were also discussed. To better understand the role of CBX3 in glioma, a lentiviral vector expressing CBX3-shRNA and cyclin dependent kinase inhibitor 1A (CDKN1A) siRNA were established and transfected into the glioma U87 cells. Besides, the CBX3 and CDKN1A expression levels in glioma U87 cells after transfected with CBX3-shRNA were gauged by qRT-PCR and Western blot. CCK-8, colony formation and EdU assays have been applied to evaluate the influence of CBX3 on U87 cells proliferation, and flow cytometry has been applied to manage the changes in cell cycle and cell apoptosis after transfection with CBX3-shRNA. Xenograft tumors have been examined in vivo for the carcinogenic effects and prognostic value of CBX3 in glioma tissues. RESULTS: In the present study, CBX3 was demonstrated to be highly expressed in human glioma tissues, and high CBX3 expression predicted the dismal recurrence-free survival (RFS) and poor overall survival (OS) for glioma patients. High CBX3 expression was dependent on the tumor size, Karnofsky performance scale (KPS) score, WHO grade, recurrence and survival status. Moreover, CBX3 expression knockdown could remarkably suppress the proliferation and colony formation ability of U87 cells, which was achieved through blocking cell arrest at G0/G1 phase and inducing apoptosis. Additionally, our findings also suggested that, compared with shRNA-Ctrl transfection, the mRNA and protein expression levels of CDKN1A have been dramatically up-regulated in vitro after transfection with shRNA-CBX3. Consistent with the results of in vitro assays, the outcomes of xenograft assay and immunohistochemistry (IHC) also indicated that, the tumor growth and Ki-67 expression level were restrained in response to CBX3 inhibition, while the CDKN1A expression level in vivo was up-regulated. Down-regulation of CDKN1A expression partially restored the ability of cell proliferation in the U87 cells, which was inhibited by shRNA-CBX3 CONCLUSIONS: In conclusion, results of the current research suggest that a high CBX3 expression level predicts the poor prognosis for glioma patients. CBX3 can stimulate the growth of glioma U87 cells through targeting CDKN1A and CBX3 may become a novel target in the clinical treatment for glioma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Zhao SP, Wang F, Yang M, et al. CBX3 promotes glioma U87 cell proliferation and predicts an unfavorable prognosis. J Neurooncol. 2019. PMID: 31502042. doi:10.1007/s11060-019-03286-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。